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16.1  Introduction 
 Therapeutic Nuclear Medicine in the United Kingdom has developed in a fairly 
inconsistent way over the last 50 years. It is a sad inditement of the state of British 
nuclear medicine that access to good therapeutic nuclear medicine has become little 
more than a “post code lottery” [ 1 ]. This in part has been due to the uneven spread 
of specialists in nuclear medicine with most posts being concentrated in the South 
East and North West. It is not therefore surprising that most therapeutic nuclear 
medicine has developed in these areas as well. Diagnostic nuclear medicine was 
traditionally performed by nuclear medicine physicians and radiologists but the 
 latter have generally showed little interest in radionuclide therapy as it was not seen 
as “radiology”. An alternate source of expertise lies with clinical oncology and in 
many parts of the U.K radionuclide therapy is delivered by clinical oncologists. 
However, as oncologists have taken a system based approach to treatment and those 
who are licenced to treat thyroid cancer may have little interest in cancers in other 
sites. Compounded to this has been decision by clinical oncologists to withdraw 
from treatment of benign disease. Some endocrinologists have taken on the role of 
treating benign thyroid disease but of course they will not do radiation synevecto-
mies. The delivery of radionuclide therapy also requires further craft group skills in 
particular trained clinical scientists, technologists, radiopharmacy and nursing. All 
this has led to a centripetal effect with expertise being concentrated in less than ten 
centres across the UK. The majority of these centres lie within Greater London 
further exacerbating the poor geographic distribution of services. The biggest 
change over the past 5 years which may be temporary change in funding with 
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central funding in England for radium-223, peptide radionuclide radiotherapy 
(PRRT) and to a lesser extent yttrium-90 particulates for selective intra-arterial 
radio- therapy (SIRT) for metastasis in the liver. For those centres who already offer 
a range of radionuclide therapies adding these newer treatments has some resource 
implications but does not normally require extensive business planning to get 
approval to start treatments. Therefore even with new funding patients have tended 
to be seen and treated in those centres who have already undertaken a range of 
radionuclide therapies. 
16.2  Radioiodine 
 The greatest success story for radionuclide therapy has been the use of I-131 for 
both benign and malignant thyroidal disease [ 2 ]. Since the fi rst treatments 70 years 
ago in Manchester most patients in the United Kingdom have access to I-131 and 
the specialist clinics that have been developed for assessing the need for treatment 
and follow-up. In benign thyroid disease it has been shown that early treatment with 
I-131 is cost effective and preferable to years of trials of anti-thyroid medication. It 
is considered routine (Fig.  16.1 ) but once was a revolution, quoting the great Ralston 
Paterson from Manchester “The fi rst point to be emphasised is that this use of radio-
iodine in thyroid cancer represents a completely new principle of therapy—the prin-
ciple of systemic ingestion with, thereafter, selective absorption of a drug carrying 
 Fig. 16.1  A series of spot gamma camera images from the 1980s showing residual uptake in the 




a radioactive element in it and resulting in a zone of localised high radiation dosage 
in the selective absorption tissues”.
 Once thought too dangerous to give to young women it would now be considered 
ideal especially if they were considering having children. In thyroid cancer, there 
has been a rare British triumph with the recent “HiLo” trial showing that for those 
with low risk cancers ablation with 1.1 GBq is as good as using 3.7 GBq [ 3 ]. This 
has resulted in a reduction in the risk of radioiodine associated morbidity and of 
much greater interest to the managers of the National Health Service a reduced 
number of days in a hospital bed. 
16.3  Relieving Bone Pain 
 The second theme in radionuclide therapy was the relief of bone pain. Initially this 
depended on the use of phosphorus-32 a bone seeking radiopharmaceutical. 
However, its long half-life resulted in a high level of bone marrow suppression. The 
next strategy was to administer a radiopharmaceutical to an area of limited disease 
and thus radiation synovectomy was developed with an emphasis of Y-90 colloids 
injected into infl amed knees. A technique which consistently delivers pain relief in 
80 % of patients to whom it is administered with relief of pain lasting 12 months or 
more. However, the number of practitioners who regularly give this safe and inex-
pensive treatments are so rare that when the author had a private practice in Harley 
Street, good business was had by fl ying patients over from New York for 
treatment. 
 Then came another British story. There remained great need for a radionuclide 
that could treat the pain from bone metastases but not have the side effects of P-32. 
Looking down the periodic table below calcium lies strontium and Sr-89 could 
deliver a soft beta with a short path length but still a long half-life. This product was 
developed by the newly privatised Amersham International with Prof Duncan 
Ackery from Southampton [ 4 ], his clinical scientist Dr Glenn Blake and two regis-
trars Sandy McEwan and Val Lewington. The science was great as 70 % of patients 
had good or complete pain relief, the marketing was abysmal. The American 
Merrell-Dow company developed a Samarium diphosphonate (Sm-153 EDTMP) as 
a sort of strontium “light” with a shorter half-life it could be used in those with 
higher disease burdens [ 5 ]. This was the fi rst radionuclide therapy in which a full 
phase III clinical trial was performed but after looking like it would be a success 
interest also fi zzled out after a decade. 
 The latest incarnation is another group-2 element Radium-223 which has 
been jointly developed by Bayer and the Norwegian company Algeta. After a 
clinical trial of 1000 patients (the largest contributing country being the UK) it 
was shown that 6 cycles of Ra-223 not only reduced the pain from bone metas-
tases of prostate cancer but patients lived longer [ 6 ]. Therefore with Ra-223 
patients liver better and liver longer. So far Ra-223 looks to be successful but 
time will tell. 
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16.4  Theranostics 
 Though the term theranostics is relatively recent, nuclear medicine has been per-
forming theranostics since the fi rst radioiodine scan. The meaning of the word ther-
anostics is not clearly defi ned but is generally understood to mean combining 
relevant diagnostic and therapeutic methods. This is ideally suited to nuclear medi-
cine and the fi rst designed theranostic agent was fi rst used in the United Kingdom 
in 1986 by the Southampton group using low activity I-131 meta-iodo benzyl gui-
nadine (MIBG) and then high activity I-131 MIBG to treat malignant phaeochro-
mocytomas [ 7 ] and later its use was expanded into other tumour types such as 
carcinoid [ 8 ] and more importantly neuroblastoma with much work being done at 
University College Hospital London (UCHL) by Drs Jamshed Bomanji and Dr 
Mark Gaze. 
 The most successful form of theranostics however, has been the use of soma-
tostatin analogues for the treatment of neuroendocrine tumours. This method was 
fi rst proposed by Prof Eric Krenning in Rotterdam [ 9 ] but using various methods 
has become more widely used in the United Kingdom with many centres using the 
optimised imaging of Ga-68 DOTATATE PET and Lu-177 DOTATATE therapy. 
Though not licenced products these agents hold European Medicine Agency orphan 
drug status. Also presently those patients being treated for disseminated neuroendo-
crine tumours which are resistant to chemotherapy or biologicals can have the 
radioactive treatment funded centrally within England. Using this approach it looks 
as though 70–80 % of patients have a good palliative outcome with a low rate 
(1–4 %) of signifi cant long lasting toxicity [ 10 ]. 
 However not all theranostic agents have proved to be so accepted Y-90 
tostisuomab is an antibody that can be used to treat CD20 expressing non-Hodgkins 
lymphomas (NHL). However, despite clear evidence that a single treatment can be 
as effective as several months of biologicals [ 11 ] it has failed to be used widely and 
must be considered a commercial failure. The reasons for this failure is unclear but 
it had to compete with other non-radioactive agents supported by large pharmaceu-
tical companies with large advertising budgets. 
 It seems that theranostic radionuclide therapy will only be allowed to be success-
ful where it does not threaten the commercial interest of large organisations but in 
reality this still gives us many rarer tumours, which often have unique targets, which 
we can aim to treat. 
16.5  The Double-Whammy 
 The basis of most radionuclide therapy has been the systemic administration of a 
product that will use a molecular target such as a somatostatin receptor and this was 
the principle laid out by Paterson in 1950. However, what if the target disease is 
limited to one organ, would it not be possible to direct a treatment to that one organ 
and maximise the radioactivity delivered and reduce the radioactive dose to other 
tissues. Since the earliest days of nuclear medicine there have been attempts to do 
this for example giving I-131 lipiodol into the leg lymphatics of a patient with 
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lymphoma or instilling Y-90 into the peritoneal cavity [ 12 ,  13 ]. The breakthrough 
came with the advances of a different technology; that of fast low dose fl uoroscopy 
and interventional catheter design. 
 The liver would be a good target, there is no doubt that primary and secondary 
tumours in the liver are unlikely to be result in a long and happy life. The liver has 
a twin arterial blood supply but uniquely primary and secondary liver tumours are 
fed by the hepatic artery but normal hepatocytes also has an additional blood supply 
via the portal vein. A catheter placed in the relevant hepatic artery will deliver a 
radioactive substance which may have a radiation and an embolic effect so the 
tumour gets a “double whammy”. 
 This idea was fi rst used in a reasonable number of patients in Rennes in France 
using I-131 Lipiodol in primary hepatocellular cancer and brought to the UK by Dr 
Andrew Hilson at the Royal Free Hospital where it was shown to be as effective as 
chemotherapy loaded lipiodol but with fewer side effects [ 14 ,  15 ]. 
 The next major steps took place in Canada with Y-90 labelled glass beads 
(Theraspheres) and in Australia Y-90 labelled resin beads (SIRspheres). In Clinical 
trials the use of these products in patients with metastases from colon cancer has been 
shown to improve survival [ 16 ]. Their use in the UK was pioneered in London by Prof 
Al-Nahhas at the Hammersmith Hospital and Dr Buxton-Thomas in Kings College 
Hospital. Presently their use is funded in 12 sites around England for evaluation by the 
radiotherapy clinical reference group in metastatic colo-rectal cancer but probably 
their greatest potential use to save lives is with hepatocelluar cancer (Fig.  16.2 ) but it 
is in this disease these treatments remain unfunded by the National Health Service.
16.6  Dosimetry 
 One area of defi ciency in radionuclide therapy has been in the fi eld of dosimetry. With 
external beam radiotherapy the distribution of radioactivity is highly predictable. This 
is not the case with systemic radionuclide therapy. Post therapy imaging is needed to 
a b
 Fig. 16.2  ( a ) A LAVA MR sequence showing a large primary HCC in segment 4. ( b ) A Y-90 Time 
of fl ight PET showing precise delivery of Y-90 resin particulates into segment 4 and localisation in 
the tumour delivering over 150 Gy tumour dose with minimal radiation to the rest of the liver 
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look for the biodistribution of agents. However, an inherent problem is that molecular 
agents may not distribute homogeneously within a target tissue and these subtle 
changes may not be picked up by a technique which has a resolution of 1–2 cm. In 
addition there are no agreed methodologies for calculating radiation doses or even 
what doses to calculate. It may be fairly easy to measure the whole body radioactivity 
every day in a patient who has received I-131 but how does that translate to a radiation 
dose to the salivary glands or even the target tumour? 
 If dosimetry is to be done and it is a legal requirement it is done there should be 
consensus on how dosimetry is done and what methods are used. In health systems 
that are becoming increasing short of resources it is vital that the radionuclide ther-
apy community identify what personnel and training is needed to deliver dosimetry 
of high quality to all sites using these treatments [ 1 ]. 
16.7  The Future 
 When the BNMS celebrates its 75th anniversary will there be a chapter on radionu-
clide therapy? This is diffi cult to know. Many of us passionately believe in these 
methods but we have to accept that even in the nuclear medicine community we are 
a minority. 
 The recent appointment of Val Lewington as the UK’s fi rst professor of Nuclear 
Medicine with a special interest in radionuclide therapy must be a step in the right 
direction, however there is much to do. Radionuclide therapy is integral to the 
nuclear medicine curriculum but how many trainees really get to be immersed in 
therapy-still too few I fear. 
 As we enter into the age of personalized medicine theranostics and radionuclide 
therapy should become more important not less. This however, will need investment 
on a scale not seen before and a cadre of trained and enthusiastic nuclear medicine 
practitioners from all craft groups. 
 Open Access This chapter is distributed under the terms of the Creative Commons Attribution-
Noncommercial 2.5 License ( http://creativecommons.org/licenses/by-nc/2.5/ ) which permits any 
noncommercial use, distribution, and reproduction in any medium, provided the original author(s) 
and source are credited. 
 The images or other third party material in this chapter are included in the work’s Creative 
Commons license, unless indicated otherwise in the credit line; if such material is not included in 
the work’s Creative Commons license and the respective action is not permitted by statutory regu-
lation, users will need to obtain permission from the license holder to duplicate, adapt or reproduce 
the material. 
 References 
  1.  Flux G, Moss L, Buscombe J, Gaze M, Guy M, Mather S, Orchard K. Molecular radiotherapy 
in the UK. London: British Institute of Radiology; 2011. 
  2.  Paterson R. The treatment of thyroid carcinoma with radioiodine. Br J Radiol. 1950;23:553–6. 
J. Buscombe
127
  3.  Mallick U, Harmer C, Yap B, et al. Ablation with low dose radioiodine and thyrotropin alfa in 
thyroid cancer. N Engl J Med. 2012;366:1674–85. 
  4.  Lewington VJ, McEwan AJ, Ackery DM, et al. A prospective randomised double blind cross-
over study to examine the effi cacy of strontium-89 in pain palliation in patients with advanced 
prostate cancer metastatic to bone. Eur J Cancer. 1991;27:954–8. 
  5.  Serafi ni AN, Houston SJ, Resche I, et al. Palliation of pain associated with metastatic bone 
pain using samarium-153 lexidronam: a double blind placebo controlled clinical trial. J Clin 
Oncol. 1998;16:1574–81. 
  6.  Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic 
prostate cancer. N Engl J Med. 2013;369:213–23. 
  7.  McEwan AJ, Shapiro B, Sisson JC, Beierwaltes WH, Ackery DM. Radio-iodobenzylguanadine for 
the scintigraphic location and therapy of adrenergic tumours. Semin Nucl Med. 1985;15:132–5. 
  8.  Prvulovich EM, Stein RC, Bomanji JB, Ledermann JA, Taylor I, Ell PJ. Iodine-131 MIBG 
therapy of a patient with carcinoid liver metastases. J Nucl Med. 1998;39:1743–5. 
  9.  Krenning EP, Kooij PP, Bakker WH, et al. Radiotherapy with a radiolabeled somatostain analogue 
[111In-DTPA-D-Phe1]-octreotide. A case history. Ann N Y Acad Sci. 1994;733:496–506. 
 10.  Buscombe J, Navalkissoor S. Molecualr radiotherapy. Clin Med. 2012;12:381–6. 
 11.  Witzig TE, Molina A, Gordon LI, et al. Long term responses in patients with recurring or 
refractory B cell non-Hodgkin lymphoma treated with yttrium-90 ibritumomab tiuxetan. 
Cancer. 2007;109;1804–10. 
 12.  Hiniakowa I, Skalska-Vorbrodt J. Intralymphatic treatment of various neoplasms with radio-
isotope I-131. Clinical considerations. Pol Przegl Radiol Med Nukl. 1971;35:83–90. 
 13.  Heneghan JB, Crook JN, Cohn I. Yttrium-90 microspheres for inhibition of intra-peritoneal 
tumor growth. Surg Forum. 1968;19:78–80. 
 14.  Bretagne JF, Raul JL, Bourguet P, et al. Hepatic artery injection of I-131 labelled lipiodol. Part 
II. Preliminary results of therapeutic use in patients with hepatocellular carcinoma and liver 
metastases. Radiology. 1988;162:547–50. 
 15.  Bhattacharya S, Novell JR, Dusciko GM, Hison AJ, Dick R, Hobbs KE. Epirubacin-Lipiodol 
chemotherapy versus 131- iodine-Lipiodol in the treatment of unresectable hepatocellular can-
cer. Cancer. 1995;76:2202–10. 
 16.  Gray B, Van Hazel G, Hope M, Burton M, Moroz P, Anderson J, Gebski V. Randomised trial 
of SIR-spheres plus chemotherapy vs chemotherapy alone for treating patients with liver 
metastases from primary bowel cancer. Ann Oncol. 2001;12:1711–20. 
16 Therapeutic Nuclear Medicine in the UK
128
 John  Buscombe  I trained in general internal medicine in London and Essex before being trained 
in Nuclear Medicine at the Middlesex Hospital, London.
 My fi rst Consultant post was at the Royal Free Hospital in London, I developed one of Europe’s 
busiest therapeutic nuclear medicine practices. This included the development of directly inject-
able radiopharmaceuticals into arteries supplying brain and liver tumours. During this time, I was 
involved in a range of research projects including Phase I and II trials in both diagnostic and thera-
peutic nuclear medicine and also acted as principal investigator in international Phase III trials. 
These trials included the use of 99mTc MIBI in identifying and risk stratifying breast cancer and 
agents for imaging lung cancer and pulmonary emboli as well as the use of radioimmunotherapy 
for colon cancer and Hodgkin’s lymphoma. 
 Since 2010 I have been working at Cambridge University Hospitals with a particular emphasis 
in cyclotron-based PET. The focus of these projects has been on the use of C-11 products in iden-
tifying sub-centimetre endocrine tumours and also PET imaging of atheroma and cardiovascular 
infl ammation. I am also a Professor of Nuclear Medicine in the University of Pretoria developing 
nuclear medicine and education in an African setting 
 I have published over 200 papers in peer-reviewed journals, written or edited s7 books and 
written over 40 book chapters. I continue to work for the nuclear medicine community in the UK 
and Europe and have been a Council Member for the British Nuclear Medicine Society twice and 
has also served on the British Nuclear Medicine Society annual meeting scientifi c committee for a 
total of 6 years. 
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